FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2568504546> ?p ?o ?g. }

• W2568504546 abstract "Abstract Effective immunotherapies rely on triggering specific cytotoxic responses against target cells. Chimeric Antigen Receptors (CAR) composed of antigen recognition domains in the form of scFv portions of monoclonal antibodies and immune cell activation domains provide non-MHC restricted, KIR-independent, immune cellmediated cytotoxicity directed toward target cells expressing specific antigens. It is well demonstrated that CAR transfection into immune cells using viral vectors redirects their specificity and enhances their cytotoxicity. Translation of these findings into clinically feasible treatment strategies is challenged by the labor/costs associated with extended cell processing, and by safety concerns associated with viral vectors. We describe here the use of non-viral methods to deliver a nucleotide sequence encoding CAR into freshly isolated immune cells obtained from peripheral blood leukapheresis collection. Protocols for loading mRNA encoding eGFP (irrelevant control) and a previously described anti-CD19 CAR (Imai et al. Blood 2005) into peripheral blood mononuclear cells (PBMC) and cell subsets (T cells, NK cells, and monocyte-depleted PBMC) were developed and optimized using a clinically validated, automated, closed-system, flow electroporation technology. PBMC were obtained from 5 normal healthy donors and 1 patient with B-cell chronic lymphocytic leukemia (B-CLL). Expression levels of eGFP or anti-CD19-BB-z were analyzed by flow cytometry. Specific cytotoxicity of target cells after 4 hours was measured by flow cytometry using acetoxymethyl-calcein labeled CD19+ target cells which included acute lymphoblastic leukemia (ALL) cell lines, primary B-CLL cells and autologous B cells. Following loading of mRNA encoding eGFP, cell viability was consistently ≥80% for all cell populations. Most cells expressed eGFP: 97±1% (day 1) and 83±2% (day 7). Following loading of mRNA encoding anti-CD19-BB-z, cell viability was 96%±1% for resting T cells (n=2), 93%±10% for PBL (n=2), 94%±8% for PBMC (n=3), 80%±15% for NK cells (n=4). Expression of anti-CD19-BB-z protein receptor was 54%±11% (day 1) in PBMC (n=6). CAR expression decreased over time and was essentially similar to baseline on day 7 post-loading. Cells expressing anti-CD19-BB-z protein (but not those expressing eGFP only), lysed 60%–80% ALL or B-CLL target cells at an effector-to-target ratio (E:T) of 8:1. A shigher E:T ratio of 20:1 was required for 60%–80% lysis of autologous B-cell targets. There was no change in cytolytic activity of CAR mRNA loaded-PBMC during the first 3 days post-loading. Subsequently, cytolytic activity dropped and on day 7 (post-loading) was approximately half of the activity measured on day 3 (post-loading). In vivo testing was performed in a sub-cutaneous tumor grafting model in Beige SCID mice. The mice (N = 5 per group) were transplanted subcutaneously with CD19+ tumor (HS Sultan) cells (1 × 106) co-mixed with PBMC loaded with anti-CD19-BB-z mRNA (doses = 0.74, 2.22, 6.67 and 20 ×106). Controls were tumor cells only or tumor cells co-mixed with unmodified PBMC. Tumors developed and grew in 3/5 animals in each control group and in 2/5 in lowest anti-CD19-BB-z mRNA-loaded dose. No tumor formation was observed in any animal in each of the 3 higher cell doses. More comprehensive animal studies and investigation of engineering additional constructs for chimeric signal receptor with tumor affinities other than anti-CD19 are in progress. These results indicate that CAR can be effectively transfected into immune cells with the methodology that we developed. Because of its simplicity and effectiveness, this methodology is well suited for clinical application and holds promise for improving the specificity and widening the feasibility of cell therapy." @default.
• W2568504546 created "2017-01-13" @default.
• W2568504546 creator A5021463288 @default.
• W2568504546 creator A5035803842 @default.
• W2568504546 creator A5049862423 @default.
• W2568504546 creator A5057463216 @default.
• W2568504546 creator A5060968083 @default.
• W2568504546 creator A5065331155 @default.
• W2568504546 creator A5070549026 @default.
• W2568504546 creator A5073654207 @default.
• W2568504546 date "2008-11-16" @default.
• W2568504546 modified "2023-09-28" @default.
• W2568504546 title "A Highly Efficient, Clinically Applicable Transfection Method to Redirect the Specificity of Immune Cells and Enhance Their Anti-Tumor Capacity" @default.
• W2568504546 doi "https://doi.org/10.1182/blood.v112.11.3894.3894" @default.
• W2568504546 hasPublicationYear "2008" @default.
• W2568504546 type Work @default.
• W2568504546 sameAs 2568504546 @default.
• W2568504546 citedByCount "0" @default.
• W2568504546 crossrefType "journal-article" @default.
• W2568504546 hasAuthorship W2568504546A5021463288 @default.
• W2568504546 hasAuthorship W2568504546A5035803842 @default.
• W2568504546 hasAuthorship W2568504546A5049862423 @default.
• W2568504546 hasAuthorship W2568504546A5057463216 @default.
• W2568504546 hasAuthorship W2568504546A5060968083 @default.
• W2568504546 hasAuthorship W2568504546A5065331155 @default.
• W2568504546 hasAuthorship W2568504546A5070549026 @default.
• W2568504546 hasAuthorship W2568504546A5073654207 @default.
• W2568504546 hasConcept C137061746 @default.
• W2568504546 hasConcept C147483822 @default.
• W2568504546 hasConcept C153911025 @default.
• W2568504546 hasConcept C154317977 @default.
• W2568504546 hasConcept C202751555 @default.
• W2568504546 hasConcept C203014093 @default.
• W2568504546 hasConcept C2777701055 @default.
• W2568504546 hasConcept C2778957590 @default.
• W2568504546 hasConcept C502942594 @default.
• W2568504546 hasConcept C54009773 @default.
• W2568504546 hasConcept C54355233 @default.
• W2568504546 hasConcept C553184892 @default.
• W2568504546 hasConcept C55493867 @default.
• W2568504546 hasConcept C81885089 @default.
• W2568504546 hasConcept C86803240 @default.
• W2568504546 hasConcept C8891405 @default.
• W2568504546 hasConceptScore W2568504546C137061746 @default.
• W2568504546 hasConceptScore W2568504546C147483822 @default.
• W2568504546 hasConceptScore W2568504546C153911025 @default.
• W2568504546 hasConceptScore W2568504546C154317977 @default.
• W2568504546 hasConceptScore W2568504546C202751555 @default.
• W2568504546 hasConceptScore W2568504546C203014093 @default.
• W2568504546 hasConceptScore W2568504546C2777701055 @default.
• W2568504546 hasConceptScore W2568504546C2778957590 @default.
• W2568504546 hasConceptScore W2568504546C502942594 @default.
• W2568504546 hasConceptScore W2568504546C54009773 @default.
• W2568504546 hasConceptScore W2568504546C54355233 @default.
• W2568504546 hasConceptScore W2568504546C553184892 @default.
• W2568504546 hasConceptScore W2568504546C55493867 @default.
• W2568504546 hasConceptScore W2568504546C81885089 @default.
• W2568504546 hasConceptScore W2568504546C86803240 @default.
• W2568504546 hasConceptScore W2568504546C8891405 @default.
• W2568504546 hasLocation W25685045461 @default.
• W2568504546 hasOpenAccess W2568504546 @default.
• W2568504546 hasPrimaryLocation W25685045461 @default.
• W2568504546 hasRelatedWork W2007802550 @default.
• W2568504546 hasRelatedWork W2079007950 @default.
• W2568504546 hasRelatedWork W2105557870 @default.
• W2568504546 hasRelatedWork W2282056688 @default.
• W2568504546 hasRelatedWork W2344883741 @default.
• W2568504546 hasRelatedWork W2512142474 @default.
• W2568504546 hasRelatedWork W2531541799 @default.
• W2568504546 hasRelatedWork W2560831255 @default.
• W2568504546 hasRelatedWork W2560899846 @default.
• W2568504546 hasRelatedWork W2562017333 @default.
• W2568504546 hasRelatedWork W2564307027 @default.
• W2568504546 hasRelatedWork W2575016736 @default.
• W2568504546 hasRelatedWork W2591060002 @default.
• W2568504546 hasRelatedWork W2973836180 @default.
• W2568504546 hasRelatedWork W2979705679 @default.
• W2568504546 hasRelatedWork W2980206906 @default.
• W2568504546 hasRelatedWork W2980687545 @default.
• W2568504546 hasRelatedWork W2991291630 @default.
• W2568504546 hasRelatedWork W3025400366 @default.
• W2568504546 hasRelatedWork W2846203330 @default.
• W2568504546 isParatext "false" @default.
• W2568504546 isRetracted "false" @default.
• W2568504546 magId "2568504546" @default.
• W2568504546 workType "article" @default.